银化物Rb1通过减少老年小鼠的DNA损伤来减轻动脉衰老
Qi Si1, Lin Wu1, Ximei Zhang1
1Department of Cardiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Experimental gerontology
|December 24, 2025
概括
在老年小鼠中,用金色化物Rb1 (Rb1) 治疗通过减少DNA损伤和亡,改善了大动脉结构和生物机械功能. 这表明Rb1具有延缓血管衰老和相关心血管疾病的治疗潜力.
科学领域:
- 心血管研究研究心血管研究
- 生物老龄化 生物老龄化
- 药理学 药理学是指药理学的学科.
背景情况:
- 血管衰老是心血管疾病的主要危险因素,其特点是结构和功能衰退.
- 与年龄相关的血管恶化背后的精确分子机制仍然不完全理解.
- 人参中的关键化合物 - - 人参酸Rb1 (Rb1) 显示出对抗衰老效果的前景.
研究的目的:
- 评估Rb1对老鼠大动脉的保护作用.
- 阐明Rb1抗血管衰老作用的分子机制.
- 提供Rb1作为血管衰老的潜在天然治疗剂的证据.
主要方法:
- 年老的小鼠接受了Rb1或PBS注射6周;年轻的小鼠作为对照.
- 大动脉组织通过组织形态学,纳米生物力学 (AFM) 和衰老/亡/DNA损伤标志物 (P21,SA-β-gal,TUNEL,γ-H2AX) 进行了分析.
主要成果:
- Rb1治疗改善了大动脉结构重塑,并恢复了光滑肌肉细胞对齐和细胞外基质.
- 原子力显微镜揭示了Rb1改善了大动脉纳米生物力学性质的因年龄而引起的损伤.
- Rb1显著降低了DNA损伤标志物γ-H2AX,P21表达,SA-β-gal阳性和亡 (TUNEL),延迟了血管衰老.
结论:
- 在衰老的大动脉中,Rb1有效地减轻了DNA损伤,结构重塑和生物机械功能障碍.
- Rb1延迟了血管衰老和亡,可能是通过向DNA损伤途径.
- Rb1显示出与年龄相关的大动脉损伤的治疗潜力显著.
相关概念视频
Aging
561
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
561
Pharmacodynamics in Geriatric Patients: Effects of Age
174
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
174


